Quantrx Biomedical (OTCMKTS:QTXB) and Westaim (OTCMKTS:WEDXF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.
Risk and Volatility
Quantrx Biomedical has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500. Comparatively, Westaim has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.
This table compares Quantrx Biomedical and Westaim’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Westaim pays an annual dividend of $0.10 per share and has a dividend yield of 4.7%. Quantrx Biomedical does not pay a dividend.
This is a breakdown of current ratings and price targets for Quantrx Biomedical and Westaim, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation and Earnings
This table compares Quantrx Biomedical and Westaim’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Westaim||$3.70 million||81.65||$5.57 million||N/A||N/A|
Westaim has higher revenue and earnings than Quantrx Biomedical.
Westaim beats Quantrx Biomedical on 7 of the 8 factors compared between the two stocks.
Quantrx Biomedical Company Profile
QuantRx Biomedical Corporation engages in the development and commercialization patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market, based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infections, urinary incontinences, general catamenial uses, and other medical needs. It also provides InSync, a feminine hygienic interlabial padand; Unique miniform, which is available as a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad, for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. The company was incorporated in 1986 and is based in Tualatin, Oregon.
Westaim Company Profile
The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.
Receive News & Ratings for Quantrx Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantrx Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.